CHENGDU, China, Dec. 23, 2024 /PRNewswire/ -- Keymed Biosciences Inc. (HKEX: 02162) today announced the National Medical Products Administration (the "NMPA") of China has recently approved the supplemental New Drug Application (the "sNDA") of Stapokibart (anti-IL-4Rα monoclonal antibody,...
Read More Details
Finally We wish PressBee provided you with enough information of ( Keymed Biosciences Announces Approval Of Stapokibart For The Treatment Of Chronic Rhinosinusitis With Nasal Polyposis )
Also on site :
- The 36 US bases on the frontline of Iranian retribution
- Target's 'Top-Selling' $5 Backpack Is Heading Back to Stores This Year
- Fresh sirens in north Israel warning of Iran missiles: army